AtonRa Partners Reduces Position in TransMedics Group, Inc. (NASDAQ:TMDX)

AtonRa Partners cut its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 8.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,193 shares of the company’s stock after selling 1,094 shares during the period. TransMedics Group comprises 1.8% of AtonRa Partners’ portfolio, making the stock its 5th biggest position. AtonRa Partners’ holdings in TransMedics Group were worth $883,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. J.W. Cole Advisors Inc. purchased a new stake in shares of TransMedics Group in the 3rd quarter worth $929,000. Bank of New York Mellon Corp lifted its holdings in shares of TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after buying an additional 363,012 shares during the period. Shariaportfolio Inc. purchased a new stake in shares of TransMedics Group in the 3rd quarter worth $470,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of TransMedics Group by 12.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company’s stock worth $378,000 after buying an additional 763 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of TransMedics Group by 12.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company’s stock worth $818,000 after buying an additional 1,700 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Waleed H. Hassanein sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total value of $380,480.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $7,047,155.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 736 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the completion of the transaction, the insider now owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 4,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total value of $380,480.00. Following the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,047,155.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 117,078 shares of company stock valued at $9,972,971. 7.00% of the stock is owned by company insiders.

TransMedics Group Price Performance

NASDAQ TMDX traded up $5.17 during trading hours on Monday, reaching $97.25. The company’s stock had a trading volume of 1,259,048 shares, compared to its average volume of 691,487. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of -126.30 and a beta of 1.99. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $99.63. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The company’s 50-day moving average is $82.98 and its two-hundred day moving average is $74.89.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The company had revenue of $81.20 million during the quarter, compared to analysts’ expectations of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. TransMedics Group’s quarterly revenue was up 158.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.21) EPS. On average, equities analysts predict that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Analysts Set New Price Targets

TMDX has been the subject of a number of analyst reports. Piper Sandler initiated coverage on TransMedics Group in a research note on Thursday, March 28th. They set an “overweight” rating and a $95.00 price objective for the company. Morgan Stanley lifted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. boosted their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Finally, Oppenheimer upped their target price on TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $102.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.